Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OPIANT PHARMACEUTICALS, INC.OPNT · Entity 115992 | Chief Commercial Officer | September 20, 2019 | September 20, 2019 |
| RxSight, Inc.RXST · Entity 1226 | Director · President and CEO | July 24, 2026 | July 25, 2026 |
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Chief Commercial Officer | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OPIANT PHARMACEUTICALS, INC.
Report date September 20, 2019 · Filed September 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,500 |
Reported balance
Holding disclosure · report date 2019-09-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 13,500 F1: 13,500 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of September 15, 2020, September 15, 2021, September 15, 2022 and September 15, 2023, subject to the Reporting Person continuing as a service provider through each such date. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $14.51 · Expires 2030-09-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-09-20 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: One-fourth of the shares subject to the option vest on September 16, 2020 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 13,500 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of September 15, 2020, September 15, 2021, September 15, 2022 and September 15, 2023, subject to the Reporting Person continuing as a service provider through each such date.
F2: One-fourth of the shares subject to the option vest on September 16, 2020 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
RxSight, Inc.
Report date July 24, 2026 · Filed July 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 2,312,138 |
Reported balance
After 2026-07-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-24 · Grant · Acquired 2,312,138 · Balance 2,312,138 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Inducement Equity Incentive Plan) through each applicable date, twenty percent (20%) of the RSUs subject to the award shall vest on the one year anniversary of the grant date, twenty percent (20%) of the RSUs subject to the award shall vest on the two year anniversary of the grant date, and 60% of the RSUs subject to the award shall vest on the three year anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.19 · Expires 2036-07-23 | Direct | 571,286 |
Reported balance
After 2026-07-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-24 · Grant · Acquired 571,286 · Balance 571,286 F3: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Inducement Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and, thereafter, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 24, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Inducement Equity Incentive Plan) through each applicable date, twenty percent (20%) of the RSUs subject to the award shall vest on the one year anniversary of the grant date, twenty percent (20%) of the RSUs subject to the award shall vest on the two year anniversary of the grant date, and 60% of the RSUs subject to the award shall vest on the three year anniversary of the grant date.
F3: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Inducement Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and, thereafter, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 24, 2026.
Tarsus Pharmaceuticals, Inc.
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,480 |
Ending reported balance
After 2026-03-19 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-03-17 · Sale · Disposed 4,286 · Balance 70,250 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Row 2 · 2026-03-18 · Sale · Disposed 4,330 · Balance 65,920 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Row 3 · 2026-03-19 · Sale · Disposed 4,440 · Balance 61,480 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2026 Filed Jul 25, 2026 00:07 UTC | RxSight, Inc. RXST · Entity 1226 | GrantStock Option (right to buy) · Derivative | 571,286 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001193125-26-316544 · ownership.xml · derivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 571,286 Underlying: Common Stock · 571,286 shares Expires 2036-07-23 F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Inducement Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and, thereafter, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 24, 2026. Read SEC document |
| July 24, 2026 Filed Jul 25, 2026 00:07 UTC | RxSight, Inc. RXST · Entity 1226 | GrantRestricted Stock Unit · Derivative | 2,312,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-316544 · ownership.xml · derivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,312,138 Underlying: Common Stock · 2,312,138 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Inducement Equity Incentive Plan) through each applicable date, twenty percent (20%) of the RSUs subject to the award shall vest on the one year anniversary of the grant date, twenty percent (20%) of the RSUs subject to the award shall vest on the two year anniversary of the grant date, and 60% of the RSUs subject to the award shall vest on the three year anniversary of the grant date. F2 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Inducement Equity Incentive Plan) through each applicable date, twenty percent (20%) of the RSUs subject to the award shall vest on the one year anniversary of the grant date, twenty percent (20%) of the RSUs subject to the award shall vest on the two year anniversary of the grant date, and 60% of the RSUs subject to the award shall vest on the three year anniversary of the grant date. Read SEC document |
| March 19, 2026 Filed Mar 19, 2026 23:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,440 | $67.00 | $297,480.00 |
DisclosureSEC source: 0001788542-26-000007 · wk-form4_1773961455.xml · nonDerivative · entry 3 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,480 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 23:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,330 | $68.71 | $297,514.30 |
DisclosureSEC source: 0001788542-26-000007 · wk-form4_1773961455.xml · nonDerivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,920 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 23:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,286 | $69.42 | $297,534.12 |
DisclosureSEC source: 0001788542-26-000007 · wk-form4_1773961455.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,250 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 5,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001788542-26-000005 · wk-form4_1773779561.xml · derivative · entry 5 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,574 Underlying: Common Stock · 5,524 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service. F7 · derivative.expiration_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 8,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001788542-26-000005 · wk-form4_1773779561.xml · derivative · entry 4 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,040 Underlying: Common Stock · 8,020 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 8,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001788542-26-000005 · wk-form4_1773779561.xml · derivative · entry 3 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,148 Underlying: Common Stock · 8,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001788542-26-000005 · wk-form4_1773779561.xml · derivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026. F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 26,482 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001788542-26-000005 · wk-form4_1773779561.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 497 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 19,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001788542-26-000003 · wk-form4_1773086801.xml · derivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,306 Underlying: Common Stock · 19,306 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 30,724 | $0.00 Strike: $74.90 | $0.00 |
DisclosureSEC source: 0001788542-26-000003 · wk-form4_1773086801.xml · derivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,724 Underlying: Common Stock · 30,724 shares Expires 2036-03-04 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:50 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 17,500 | $43.76 | $765,800.00 |
DisclosureSEC source: 0001819790-25-000081 · wk-form4_1749675042.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,557 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2025. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $43.42 to $44.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 01:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 3,365 | $50.11 | $168,620.15 |
DisclosureSEC source: 0001819790-25-000059 · wk-form4_1742521788.xml · nonDerivative · entry 3 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,057 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 01:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 3,557 | $47.40 | $168,601.80 |
DisclosureSEC source: 0001819790-25-000059 · wk-form4_1742521788.xml · nonDerivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,422 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 18, 2025 Filed Mar 21, 2025 01:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 3,643 | $46.29 | $168,634.47 |
DisclosureSEC source: 0001819790-25-000059 · wk-form4_1742521788.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,979 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:38 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 8,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000042 · wk-form4_1742348322.xml · derivative · entry 4 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,060 Underlying: Common Stock · 8,019 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:38 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 8,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000042 · wk-form4_1742348322.xml · derivative · entry 3 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,296 Underlying: Common Stock · 8,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:38 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000042 · wk-form4_1742348322.xml · derivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,790 Underlying: Common Stock · 4,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:38 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 20,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-25-000042 · wk-form4_1742348322.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 590 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024 and December 31, 2024. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:19 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 22,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000026 · wk-form4_1741382357.xml · derivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,098 Underlying: Common Stock · 22,098 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:19 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 33,691 | $0.00 Strike: $44.54 | $0.00 |
DisclosureSEC source: 0001819790-25-000026 · wk-form4_1741382357.xml · derivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,691 Underlying: Common Stock · 33,691 shares Expires 2035-03-04 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 23:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,766 | $30.60 | $145,839.60 |
DisclosureSEC source: 0001819790-24-000047 · wk-form4_1710889691.xml · nonDerivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,075 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 8,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000047 · wk-form4_1710889691.xml · derivative · entry 4 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,444 Underlying: Common Stock · 8,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000047 · wk-form4_1710889691.xml · derivative · entry 3 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,580 Underlying: Common Stock · 4,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 12,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-24-000047 · wk-form4_1710889691.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 97 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2023. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:12 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 32,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000034 · wk-form4_1710191542.xml · derivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,079 Underlying: Common Stock · 32,079 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:12 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 47,500 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001819790-24-000034 · wk-form4_1710191542.xml · derivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2034-03-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:46 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,400 | $20.05 | $48,120.00 |
DisclosureSEC source: 0001788542-23-000006 · wk-form4_1689976000.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,806 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $20.00 to $20.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 120 shares acquired under the Issuer's employee stock purchase plan on June 30, 2023. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:25 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 100 | $20.00 | $2,000.00 |
DisclosureSEC source: 0001209191-23-036395 · doc4.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,086 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2022. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 23:16 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,500 | $19.34 | $48,350.00 |
DisclosureSEC source: 0001209191-23-035579 · doc4.xml · nonDerivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,186 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2022. F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $19.02 to $19.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 23:16 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,143 | $18.61 | $39,881.23 |
DisclosureSEC source: 0001209191-23-035579 · doc4.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,686 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $18.07 to $18.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:46 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 372 | $12.15 | $4,519.80 |
DisclosureSEC source: 0001788542-23-000004 · wf-form4_167961515955541.xml · nonDerivative · entry 3 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,829 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:46 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 357 | $12.64 | $4,512.48 |
DisclosureSEC source: 0001788542-23-000004 · wf-form4_167961515955541.xml · nonDerivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,201 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:46 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 349 | $12.89 | $4,498.61 |
DisclosureSEC source: 0001788542-23-000004 · wf-form4_167961515955541.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,558 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 23:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 358 | $12.61 | $4,514.38 |
DisclosureSEC source: 0001788542-23-000002 · wf-form4_167944011481271.xml · nonDerivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,907 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 339 | $13.28 | $4,501.92 |
DisclosureSEC source: 0001788542-23-000002 · wf-form4_167944011481271.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,265 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 22:17 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 336 | $13.43 | $4,512.48 |
DisclosureSEC source: 0001209191-23-019879 · doc4.xml · nonDerivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,604 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:17 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019879 · doc4.xml · derivative · entry 3 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,370 Underlying: Common Stock · 4,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:17 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 4,790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-019879 · doc4.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 421 shares acquired under the Issuer's employee stock purchase plan on December 31, 2022. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 00:25 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 32,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017999 · doc4.xml · derivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,592 Underlying: Common Stock · 32,592 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 00:25 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 48,116 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017999 · doc4.xml · derivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,116 Underlying: Common Stock · 48,116 shares Expires 2033-03-08 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 8, 2024, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 6,857 | $17.72 | $121,506.04 |
DisclosureSEC source: 0001788542-22-000006 · wf-form4_166872420553318.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,729 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2022. F2 · shares: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $17.44 to $18.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:25 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 772 | $0.45 Strike: $0.45 | $347.40 |
DisclosureSEC source: 0001788542-22-000004 · wf-form4_166154550807584.xml · derivative · entry 4 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 772 shares Expires 2028-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted under the Plan. 25% of the option shares vested and became exercisable on July 27, 2019 and the remaining option shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:25 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,416 | $10.99 Strike: $10.99 | $48,531.84 |
DisclosureSEC source: 0001788542-22-000004 · wf-form4_166154550807584.xml · derivative · entry 3 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,573 Underlying: Common Stock · 4,416 shares Expires 2030-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:25 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 772 | $0.45 | $347.40 |
DisclosureSEC source: 0001788542-22-000004 · wf-form4_166154550807584.xml · nonDerivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:25 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 4,416 | $10.99 | $48,531.84 |
DisclosureSEC source: 0001788542-22-000004 · wf-form4_166154550807584.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 470 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 725 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:10 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 19,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001788542-22-000002 · wf-form4_164703293653715.xml · derivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,160 Underlying: Common Stock · 19,160 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:10 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 65,312 | $0.00 Strike: $19.59 | $0.00 |
DisclosureSEC source: 0001788542-22-000002 · wf-form4_164703293653715.xml · derivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,312 Underlying: Common Stock · 65,312 shares Expires 2032-03-08 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 9, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 23:29 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 1,889 | $28.11 | $53,099.79 |
DisclosureSEC source: 0001819790-21-000055 · wf-form4_163658697878613.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,203 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2021. F2 · shares: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $28.00 to $28.56. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.